FDA Discovers Microbial Contamination in Compound Pharmacy Products
Biopharma News
Advertisement
The company is cited for using unapproved visual-inspection methods for finished parenteral drugs and conducting inadequate visual inspections.
Modular containment room at Belfast facility allows studies of biologics and vaccines.
Program aims to develop a novel oral treatment.
Advertisement
Advertisement
Trending on BioPharm International
1
Launch in Lockstep: Biopharma Readiness for the CNPV’s Accelerated Clock
2
How Miniaturized Analytics Are Transforming Aseptic Bioprocessing Control
3
How Programmable Biology Could Reshape Biologic Drug Development
4
Industry Experts Probe CNPV Impacts
5
